Ken Iseri

Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial

Ken Iseri, Makoto Watanabe, Hisako Yoshikawa et al. · Journal of Bone and Mineral Research · 2019 · 103 citations

Medicine, Nephrology, Bone Metabolism +16

Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy

Kei Hihara, Masayuki Iyoda, Shohei Tachibana et al. · PLoS ONE · 2016 · 64 citations · Full text

Medicine, Nephrology, Pathology +13

Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy

Yukihiro Wada, Kei Matsumoto, Taihei Suzuki et al. · PLoS ONE · 2018 · 63 citations · Full text

Medicine, Nephrology, Pathology +17

The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial

Ken Iseri, Masayuki Iyoda, Makoto Watanabe et al. · PLoS ONE · 2018 · 61 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Long-Term Effect of Denosumab on Bone Disease in Patients with CKD

Ken Iseri, Masahide Mizobuchi, Renaud Winzenrieth et al. · Clinical Journal of the American Society of Nephrology · 2023 · 38 citations · Full text

Medicine, Clinical Sciences, Nephrology +17